Article info
Therapeutics/Prevention
Systematic review with meta analysis
Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes
- Correspondence to Dr Victor M Montori, Knowledge and Evaluation Research Unit and Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; montori.victor{at}mayo.edu
Citation
Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes
Publication history
- First published October 18, 2016.
Online issue publication
November 23, 2016
Article Versions
- Previous version (18 October 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/